DDInter1947 DDInter1082
Vorinostat (rINN) or suberoylanilide hydroxamic acid (SAHA), is a drug currently under investigation for the treatment of cutaneous T cell lymphoma (CTCL), a type of skin cancer, to be used when the disease persists, gets worse, or comes back during or after treatment with other medicines. It is the first in a new class of agents known as histone deacetylase inhibitors. A recent study suggested that vorinostat also possesses some activity against recurrent glioblastoma multiforme, resulting in a median overall survival of 5.7 months (compared to 4 - 4.4 months in earlier studies). Further brain tumor trials are planned using combinations of vorinostat with other drugs.
Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type II diabetes mellitus (T2DM). It is sold by Sanofi-Aventis under the brand name Adlyxin in the US and Lyxumia in the EU. Adlyxin recieved FDA approval July 28, 2016.
Vorinostat {u} (Compound) resembles {v} (Compound) Azelaic Acid
Vorinostat {u} (Compound) resembles {v} (Compound) Phenacemide
Vorinostat {u} (Compound) treats {v} (Disease) hematologic cancer
Vorinostat {u} (Compound) binds {v} (Gene) HDAC2
Vorinostat {u} (Compound) upregulates {v} (Gene) NFIL3
Vorinostat {u} (Compound) downregulates {v} (Gene) PLOD3
Vorinostat {u} (Compound) causes {v} (Side Effect) Neoplasm malignant
Vorinostat {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Insulin human
Vorinostat {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Canagliflozin
Vorinostat {u} may lead to a major life threatening interaction when taken with {v} Valproic acid
Vorinostat (Compound) resembles Azelaic Acid (Compound)
Vorinostat (Compound) resembles Phenacemide (Compound)
Vorinostat (Compound) treats hematologic cancer (Disease)
Vorinostat (Compound) binds HDAC2 (Gene)
Vorinostat (Compound) upregulates NFIL3 (Gene)
Vorinostat (Compound) downregulates PLOD3 (Gene)
Vorinostat (Compound) causes Neoplasm malignant (Side Effect)
Vorinostat may cause a moderate interaction that could exacerbate diseases when taken with Insulin human
Vorinostat may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
Vorinostat may lead to a major life threatening interaction when taken with Valproic acid